5 research outputs found
Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings
Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidantāantioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p[removed
High-sensitivity C-reactive protein as biomarker of inflammation in children with asthma and allergic rhinitis
Introduction. Recent researches have shown that a high-sensitivity C-reactive protein (hs-CRP) can be the
marker of chronic inflammation. The aim of the study is to investigate whether the serum hs-CRP concentration
can be used as biomarker of inflammation in children with acute asthma attack and allergic rhinitis, as well as
whether the monitoring of hs-CRP concentration can be an indicator of therapy success in children suffering
from asthma.
Methods. The study included 60 patients (30 of them with asthma and 30 with allergic rhinitis), both sexes,
aged 7 to 14 years. Apart from being questioned about personal and family history, all patients underwent
lung function and serum hs-CRP tests. The concentration of hs-CRP was measured by the latex particle immunoturbidimetric assay. In the group of children with asthma, measuring was performed before and three days
after the therapy.
Results. Patients with asthma had statistically significant higher levels of allergic sensitization, other associated
allergic diseases, higher serum IgE concentrations, and lower levels of lung functions compared with those with
allergic rhinitis. The values of hs-CRP (0.43 mg/l) were significantly higher in asthma patients than in those with
allergic rhinitis (0.21 mg/l) (p= 0.002). 26.67% of patients with asthma had the hs-CRP values above the reference range, while all patients with allergic rhinitis had hs-CRP in the reference range. After a three-day therapy, the hs-CRP values were still maintained above the reference interval in four patients with asthma (13.33%)
Conclusion. The research has showed that hs-CRP can be used as a biomarker of acute allergic inflammation
in children with asthma and thus be a therapeutic response indicator
INFANTILNA FORMA POMPEOVE BOLESTI
Pompeova bolest je rijetko autozomno recesivno nasljedno metaboliÄko oboljenjeuzrokovano nedostatkom enzima kisele alfa glukozidaze usljed mutacije GAA gena.KarakteriÅ”e se nakupljanjem glikogena u lizozomima svih Äelija, posebno Äelija miÅ”iÄa,jetre, srca i mozga. Simptomi bolesti mogu se javiti u razlicĢitoj dobi i mogu biti razliÄitetežine, Å”to najviÅ”e zavisi od prirode mutacije i rezidualne enzimske aktivnosti. Najteži jeinfantilni oblik kod koga rano nastaju kardiomegalija, hepatomegalija, hipotonija i miÅ”iÄnaslabosti, i kod koga do smrtnog ishoda dolazi u toku prve godine života. Od 2006.godine dostupno je i odobreno lijeÄenje Pompeove bolesti enzimskom supstitucionomterapijom. UspjeÅ”nost ovog vida lijeÄenja najviÅ”e zavisi od stadija bolesti u vrijeme zapoÄinjalijeÄenja, genotipa i CRIM statusa. VeÄinom pacijenti sa CRIM negativnim statusomimaju loÅ” odgovor na lijeÄenje, viÅ”e komplikacija i samim tim loÅ”iju prognozu.U ovom radu smo prikazali prvi sluÄaj infantilne forme Pompeove bolesti koju smolijeÄili enzimskom supstitucionom terapijom u naÅ”oj zdravstvenoj ustanovi. Pompeovabolest se kod ovog pacijenta prvo manifestovala hipertrofiÄnom kardiomiopatijom iimala je brzu progresiju sa razvojem hepatomegalije, teÅ”ke hipotonije, miÅ”iÄne slabostii konaÄno srÄane i respiratorne slabosti. Enzimsku supstitucionu terapijou pacijent jepoÄeo da prima u dobi od 3 mjeseca. Odgovor na terapiju je bio loÅ” i pacijent je umrou dobi od 6 mjeseci.Smatramo da bi prepoznavanje ove bolesti u ranijoj dobi i zapoÄinjanje lijeÄenja prijerazvoja kliniÄkih simptoma vjerojatno dalo bolji rezultat lijeÄenja i produžilo životnivijek oboljelih od Pompeove bolesti
PREDIKTIVNI FAKTORI AKUTNE TOKSIÄNOSTI TERAPIJE U DJECE SA AKUTNOM LIMFOBLASTNOM LEUKEMIJOM
Savremenom terapijom akutne limfoblastne leukemije (ALL) koja podrazumijeva intenzifikaciju imodeliranje citostatske terapije, danas je postignut znaÄaj napredak u lijeÄenju ovih bolesnika. Mi smo analizirali moguÄeprediktivne faktore akutne toksiÄnosti hemioterapije u toku lijeÄenja ALL djeÄije dobi
HISTIOCITOZA LANGERHANSOVIH ÄELIJA - OD JEDNOSISTEMSKOG DO MULTISISTEMSKOG OBLIKA
Histiocitoza Langerhansovih Äelija je rijetko oboljenje nastalo usljed proliferacije antigen prezentujuÄihLangerhansovih dendriditiÄnih Äelija iz koÅ”tane srži koje infiltriÅ”u razliÄite organe. Bolest je nepredvidivog toka, od moguÄespontane remisije pa do teÅ”kih diseminovanih oblika sa oÅ”teÄenjem vitalnih organa i letalnim ishodom uprkos primjenjenojterapiji.U radu je prikazan sluÄaj 22 mjeseca stare djevojÄice kod koje su se od drugog mjeca života javile promjenepo koži sa tendencijom pogorÅ”anja tokom vremena. U dobi od 22 mjeseca djevojÄici je verifikovana tumorska masa izalijevog uha sa znacima diabetes insipidusa (žedjanje, poliurija, polidipsija). Dijagnoza LCH je postvaljena patohistoloÅ”ki naosnovu bioptata kože i tumorske mase lijeve temporalne kosti. Uprkos terapiji bolest se reaktivirala nakon godinu danaterapije zbog Äega je primjenjena i sekundarna hemoterapija. Usljed razvijenog diabetes inspidusa uvedena je doživotnasupstituciona terapija antiduretskim hormonom.Izolovane kožne lezije koje ne reaguju na lokalnu terapiju i koje imaju tendenciju pogorÅ”anja bi trebale pobuditisumnju na LCH. U ovim sluÄajevima dodatna ispitivanja i bipsija kože su mandatorni radi blagovremene potvrde dijagnozei adekvatnog lijeÄenja. Uprkos terapiji djeca sa razvijenim multisistemskim oblikom bolesti mogu imati neadekvatanodgovor na terapiju